CL2024003318A1 - Control de calidad de proteína y bag3 en el cerebro - Google Patents

Control de calidad de proteína y bag3 en el cerebro

Info

Publication number
CL2024003318A1
CL2024003318A1 CL2024003318A CL2024003318A CL2024003318A1 CL 2024003318 A1 CL2024003318 A1 CL 2024003318A1 CL 2024003318 A CL2024003318 A CL 2024003318A CL 2024003318 A CL2024003318 A CL 2024003318A CL 2024003318 A1 CL2024003318 A1 CL 2024003318A1
Authority
CL
Chile
Prior art keywords
bag3
disease
brain
quality control
protein quality
Prior art date
Application number
CL2024003318A
Other languages
English (en)
Spanish (es)
Inventor
M Feldman Arthur
Myers Valerie
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of CL2024003318A1 publication Critical patent/CL2024003318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024003318A 2022-05-03 2024-10-29 Control de calidad de proteína y bag3 en el cerebro CL2024003318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263337914P 2022-05-03 2022-05-03

Publications (1)

Publication Number Publication Date
CL2024003318A1 true CL2024003318A1 (es) 2025-03-21

Family

ID=88646932

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024003318A CL2024003318A1 (es) 2022-05-03 2024-10-29 Control de calidad de proteína y bag3 en el cerebro

Country Status (11)

Country Link
US (1) US20250289858A1 (OSRAM)
EP (1) EP4518882A4 (OSRAM)
JP (1) JP2025514489A (OSRAM)
KR (1) KR20250010008A (OSRAM)
CN (1) CN119255814A (OSRAM)
AU (1) AU2023265031A1 (OSRAM)
CA (1) CA3250880A1 (OSRAM)
CL (1) CL2024003318A1 (OSRAM)
IL (1) IL316559A (OSRAM)
MX (1) MX2024013495A (OSRAM)
WO (1) WO2023215266A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4705326A1 (en) * 2023-05-02 2026-03-11 Research Institute at Nationwide Children's Hospital Gene therapy for treatment of protein misfolding diseases
CN120478386B (zh) * 2025-07-18 2025-10-17 南京大学 一种用于预防、改善和/或治疗阿尔茨海默症的siRNA及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
CA3228845A1 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction
CN109937045A (zh) * 2016-08-11 2019-06-25 天普大学-联邦高等教育系统 局部缺血/再灌注损伤
CN113286588A (zh) * 2018-10-19 2021-08-20 阿克里普斯一有限公司 神经性疾病的治疗
US20220023350A1 (en) * 2018-11-04 2022-01-27 Figene, Llc Treatment of cerebral hypoxia including stroke, chronic traumatic encephalopathy, and traumatic brain injury
WO2020150377A1 (en) * 2019-01-15 2020-07-23 Temple University - Of The Commonwealth System Of Higher Education Targeting the bag family for the treatment of neurodegenerative disease
WO2023069744A1 (en) * 2021-10-22 2023-04-27 Temple University Of The Commonwealth System Of Higher Education Bag3 methods and uses for treatment of inflammation

Also Published As

Publication number Publication date
EP4518882A4 (en) 2026-04-22
MX2024013495A (es) 2025-02-10
WO2023215266A1 (en) 2023-11-09
EP4518882A1 (en) 2025-03-12
CN119255814A (zh) 2025-01-03
JP2025514489A (ja) 2025-05-02
AU2023265031A1 (en) 2024-11-28
US20250289858A1 (en) 2025-09-18
IL316559A (en) 2024-12-01
KR20250010008A (ko) 2025-01-20
CA3250880A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
MX2024013495A (es) Control de calidad de proteina y bag3 en el cerebro
CL2023000468A1 (es) Agonistas de bicicloheptano pirrolidina de los receptores de orexina.
NZ526868A (en) Substituted alkylamine derivatives and methods of use for treating cancer and angiogenesis related disorders
AR119259A1 (es) Anticuerpos anti-cd33 y métodos de uso de los mismos
MX2022000709A (es) Regimenes de tratamiento con dexmedetomidina no sedante.
BRPI0514199A (pt) método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2019006645A (es) Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades.
JOP20230128A1 (ar) مركبات صيدلانية
MX2022010693A (es) Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades.
BR112023025330A2 (pt) Método de tratamento de pacientes deprimidos com cognição fraca e seleção de outros pacientes beneficiados com agente benzilpiperazina-aminopiridina
WO2022020391A3 (en) Precision targeted retromer therapeutics for the treatment of neurodegenerative diseases and disorders
BR112021017436A2 (pt) Composições farmacêuticas para tratamento de doenças ou transtornos oculares
MX2019014597A (es) Inhibidores de pirazolopirimidina de pde9.
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
CL2019001105A1 (es) Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño.
MX2021000515A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
ES2121791T3 (es) Composicion farmaceutica para el tratamiento o la prevencion de un tumor maligno.
MY209459A (en) Peptide conjugates of microtubule-targeting agents as therapeutics
CR20240114A (es) Derivados de s–alaninato sustituidos
MX2022013770A (es) Relaxinas modificadas y metodos de uso de las mismas.
PA8572601A1 (es) Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b
ZA202304463B (en) Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
PH12022552645A1 (en) Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases